Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Breast Neoplasms × Crizotinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 38 Lung Neoplasms 10 Neoplasm Metastasis 6 Lymphoma, Large-Cell, Anaplastic 6 Neoplasms 4 Multiple Myeloma 4 Lymphoma 4 Adenocarcinoma 4 Neuroblastoma 3 Granuloma, Plasma Cell 3 Colorectal Neoplasms 3 Uveal Melanoma 2 Recurrence 2 Hematologic Neoplasms 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Carcinoma, Renal Cell 2 Carcinoma 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma, Alveolar 1 Relapsed Pediatric Solid Tumor 1 Rare Tumor 1 Multiple Endocrine Neoplasia Type 2a 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lung Adenocarcinoma Metastatic 1

Interventions

Trastuzumab 527 Paclitaxel 501 Cyclophosphamide 482 Docetaxel 425 Capecitabine 359 Letrozole 312 Fulvestrant 276 Doxorubicin 254 Carboplatin 241 Tamoxifen 227 Anastrozole 189 exemestane 182 Radiotherapy 181 Epirubicin 179 Bevacizumab 172 Vinorelbine 151 Lapatinib 151 Gemcitabine 149 pembrolizumab 145 pertuzumab 143 palbociclib 135 Exercise 116 Albumin-Bound Paclitaxel 107 Magnetic Resonance Spectroscopy 104 Fluorouracil 104 eribulin 99 130-nm albumin-bound paclitaxel 95 Everolimus 90 Taxes 85 Cisplatin 84

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02074878 2017-08-09

CRIZENT

Baylor Breast Care Center

Phase 1 Terminated

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡